Equities research analysts expect Axovant Sciences Ltd (NASDAQ:AXON) to announce earnings of ($0.49) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.56). Axovant Sciences reported earnings of ($0.48) per share during the same quarter last year, which indicates a negative year over year growth rate of 2.1%. The company is scheduled to announce its next earnings report on Tuesday, February 13th.

On average, analysts expect that Axovant Sciences will report full year earnings of ($2.18) per share for the current year, with EPS estimates ranging from ($2.44) to ($1.80). For the next year, analysts anticipate that the business will post earnings of ($2.02) per share, with EPS estimates ranging from ($2.65) to ($1.22). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Axovant Sciences.

AXON has been the subject of a number of research analyst reports. Oppenheimer reiterated a “buy” rating and issued a $30.00 target price on shares of Axovant Sciences in a research report on Monday, September 25th. Jefferies Group set a $40.00 price target on shares of Axovant Sciences and gave the company a “buy” rating in a report on Friday, August 25th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Axovant Sciences in a report on Wednesday, September 27th. BidaskClub upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. Finally, Robert W. Baird restated a “hold” rating and set a $6.00 price target on shares of Axovant Sciences in a report on Wednesday, November 1st. Four analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $14.13.

Several institutional investors have recently added to or reduced their stakes in AXON. Bank of America Corp DE grew its stake in Axovant Sciences by 38.9% in the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Axovant Sciences by 38.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 2,789 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Axovant Sciences by 32.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 49,800 shares of the biotechnology company’s stock valued at $1,155,000 after buying an additional 12,200 shares during the last quarter. Rhumbline Advisers grew its stake in Axovant Sciences by 26.1% in the 2nd quarter. Rhumbline Advisers now owns 32,514 shares of the biotechnology company’s stock valued at $754,000 after buying an additional 6,728 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in Axovant Sciences in the 2nd quarter valued at $464,000. Institutional investors and hedge funds own 96.93% of the company’s stock.

Shares of Axovant Sciences (AXON) opened at $5.27 on Tuesday. Axovant Sciences has a 12-month low of $4.60 and a 12-month high of $27.98. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94.

TRADEMARK VIOLATION WARNING: “Axovant Sciences Ltd (AXON) Expected to Announce Earnings of -$0.49 Per Share” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/axovant-sciences-ltd-axon-expected-to-announce-earnings-of-0-49-per-share/1758391.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.